PS-1001
Immunology & Inflammation
Pre-clinicalActive
Key Facts
About Paratus Sciences
Paratus Sciences is an early-stage, private biotech pioneering a novel drug discovery approach inspired by bat biology. The company has announced its first development candidate, PS-1001, for immunology and inflammation, indicating progression from platform validation to program advancement. Backed by strategic partnerships and a world-class team, Paratus aims to translate the exceptional disease resistance and metabolic traits of bats into a new class of human therapeutics. Its success hinges on validating its unique platform and advancing its pipeline through clinical development.
View full company profileTherapeutic Areas
Other Immunology & Inflammation Drugs
| Drug | Company | Phase |
|---|---|---|
| YUSIMRY® (adalimumab-fkjp) | Meitheal Pharmaceuticals | Approved |
| TNFR1 Antagonist | AI Proteins | Discovery |
| Immunology Collaboration (J&J) | Flexomics | Discovery/Research |
| IMM-001 | RapaFusyn Pharmaceuticals | Preclinical |
| IMM-002 | RapaFusyn Pharmaceuticals | Preclinical |
| IMM-003 | RapaFusyn Pharmaceuticals | Preclinical |